Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Curaleaf Hldgs Inc. (CURLF)

  • Business News
  • Dec. 19, 2025, 12:45 UTC
  • 18
  • 1 comments

Curaleaf Announces Termination of Equity Purchase Agreement with The Cannabist Company

Market reaction Comment Full text

Mangoceuticals Inc (MGRX)

  • Business News
  • Dec. 19, 2025, 12:30 UTC
  • 17
  • 1 comments

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Market reaction Comment Full text

Castle Biosciences Inc (CSTL)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 15
  • 1 comments

Castle Biosciences - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

ProPhase Labs Inc. (PRPH)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 15
  • 1 comments

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Market reaction Comment Full text

Leap Therapeutics Inc (LPTX)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 14
  • 1 comments

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Market reaction Comment Full text

Evaxion Biotech A/S (EVAX)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 16
  • 1 comments

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Market reaction Comment Full text

OKYO Pharma (OKYO)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 12
  • 1 comments

OKYO Pharma to Ring the Opening Bell at Nasdaq

Market reaction Comment Full text

Castle Biosciences Inc (CSTL)

  • Business News
  • Dec. 19, 2025, 12:00 UTC
  • 14
  • 1 comments

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

Altimmune Inc (ALT)

  • Business News
  • Dec. 19, 2025, 11:30 UTC
  • 16
  • 1 comments

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Market reaction Comment Full text

Grifols (GRFS)

  • Business News
  • Dec. 19, 2025, 11:16 UTC
  • 16
  • 1 comments

Grifols Communication - Grifols receives US FDA approval for new fibrinogen concentrate, FESILTYTM

Market reaction Comment Full text
  • Previous
  • 272
  • 273
  • 274
  • 275
  • 276
  • Next

Search

News categories

  • Technical Exchange News(10896)
  • Event(2301)
  • SEC News(190156)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(124801)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin